Emergence Therapeutics to Attend Upcoming Conferences

Emergence Therapeutics, a new European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers, announces that Dr. Jack Elands, Chief Executive Officer of Emergence Therapeutics, will be attending the following upcoming conferences in 2020:

Bio Europe Spring
Date: March 23 – 25
Location: Virtual

ASCO
Date: May 29 – June 2
Location: Chicago

Bio International
Date: June 8 – 11
Location: San Diego

Health Tech Investor Forum
Date: June 22 – 23
Location: Paris

World ADC
Date: September 15 – 18
Location: San Diego

Bio Europe Autumn
Date: October 26 – 28
Location: Munich

If you would like to meet Dr. Elands at any of these meetings, please contact him via info@emergencetx.com.

About Emergence Therapeutics

Emergence Therapeutics is a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high-need cancers. Its lead program, ETx-1, uses innovative linker technology and the proprietary payload amanitin to target Nectin-4 – an important and validated target for a broad range of cancers. Emergence is developing ETx-01 to target cancers with Nectin-4 expression and 17p deletions, areas of high unmet need. Beyond ETx-01 Emergence is actively exploring opportunities to develop further best- or first-in-class ADCs driven by therapeutic need.

Emergence has entered into a licensing and collaboration agreement with SATT Sud-Est (the regional tech transfer office for Aix-Marseille Université, CNRS and Inserm) through which the Company has been granted exclusive rights to a set of anti-Nectin-4 antibodies developed by Dr. Marc Lopez at the Cancer Research Center of Marseille, France. SATT Sud-Est is also providing financial support to the Emergence program.

ETx-01 is being developed under a licensing and collaboration agreement with Heidelberg Pharma Research GmbH, a subsidiary of Heidelberg Pharma AG. Through this agreement Emergence has access to Heidelberg Pharma’s amanitin-based payloads and corresponding linkers (proprietary ATAC Technology). Heidelberg Pharma Research is also a founding investor in Emergence.

Emergence is led by a strong management team and is supported by a network of world-leading scientists who have contributed significantly to the field of immuno-oncology. Emergence is based in Duisburg, Germany with a subsidiary in Marseille, France. For more information, please visit: www.emergencetx.com.

Latest News

23/03/2020

Emergence Therapeutics to Attend Upcoming Conferences

Emergence Therapeutics, a new European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers, announces that Dr. Jack Elands, Chief Executive Officer of Emergence Therapeutics, will be attending the following upcoming conferences in 2020: Bio Europe Spring Date: March 23 – 25 Location: Virtual ASCO Date: May 29 – June...

View Article >
23/03/2020

Emergence Tx New Website Launch

Dr. Jack Elands, Chief Executive Officer of Emergence Therapeutics, to participate in Bio-Europe Spring digital event on 23-27 March Emergence Therapeutics, a new European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers, has launched its new company website. Emergence Therapeutics’ science is being harnessed to develop best- or first-in-class...

View Article >